Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn’s disease
Hiroyuki Okamoto, Nathanael L. Dirks, Maria Rosario, Tetsuharu Hori, Toshifumi Hibi
Intest Res. 2021;19(1):95-105.   Published online 2020 Jul 10     DOI: https://doi.org/10.5217/ir.2019.09167
Citations to this article as recorded by Crossref logo
Personalized Medicine of Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacogenetics, Therapeutic Drug Monitoring, and Beyond
Antonello Di Paolo, Giacomo Luci
Frontiers in Pharmacology.2021;[Epub]     CrossRef
Vedolizumab Immunogenicity With Long‐Term or Interrupted Treatment of Patients With Inflammatory Bowel Disease
Timothy Wyant, Lili Yang, Richard A. Lirio, Maria Rosario
The Journal of Clinical Pharmacology.2021; 61(9): 1174.     CrossRef
Combination of vedolizumab and immunomodulators in ulcerative colitis
P Pinton
Journal of Gastroenterology and Hepatology.2021;[Epub]     CrossRef